Animal testing or organoids—this question is increasingly being answered in favour of organoids. Yet robust model systems still require further research and, crucially, validation. More large pharmaceutical companies are now pursuing this goal, whether by acquiring relevant start-ups or by establishing their own research centres, as Roche has just done in Basel.
The European CDMO Model, Powering Biologics Innovation
Sponsored PublicationsEurope continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.
EIF starts €15bn fund-of-funds for scaling European tech companies
Latest NewsThe European Investment Fund has launched a new fund of funds with a target volume of €15 billion to strengthen growth financing in Europe’s technology sector. The programme is considered the largest of its kind in Europe to date and is aimed at around 100 late-stage venture capital funds.
TenBoron lands €7.6m EU grant for precision radiotherapy trials in hard-to-treat cancers
Latest NewsFinnish clinical stage biotech TenBoron Oy has landed a €7.6m grant from the European Union’s Horizon Europe Health 2025 programme. The funding will propel its boron carrier platform for a novel targeted radiotherapy into larger clinical trials for cancers with few remaining treatment options.
Immutrin secures £65m Series A for amyloid-removing heart therapy
Latest NewsImmutrin, a UK biotech, has raised £65m (€75m) in Series A funding for a pioneering antibody designed to remove pre-existing amyloid deposits in amyloidosis.
Organoids: new Roche research centre in Basel will focus on alternative model systems
Latest NewsAnimal testing or organoids—this question is increasingly being answered in favour of organoids. Yet robust model systems still require further research and, crucially, validation. More large pharmaceutical companies are now pursuing this goal, whether by acquiring relevant start-ups or by establishing their own research centres, as Roche has just done in Basel.
Sanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali Therapeutics
Latest NewsSanofi is expanding its immunology toolbox: The French pharma pays up to US$1.2bn for worldwide exclusive rights to Kali Therapeutics’ next-generation tri-specific T-cell engager targeting B cell-mediated autoimmune diseases.
Mitigating regulatory risk with holistic CMC strategies
BackgroundAs advanced therapeutic medicinal products (ATMPs) and other next-generation biologics move toward approval, Chemistry, Manufacturing and Controls (CMC) continues to be the most frequent source of regulatory concern. This article highlights recurring CMC barriers and best practices to mitigate approval delays or refusals.
Dutch biotech Laigo Bio bags €17m in oversubscribed seed round
Latest NewsMembrane protein degradation specialist Laigo Bio has completed the final close of its €17m (US$18.5m) seed financing. Funds will go towards the oncology and auto-immunity programmes based on the company’s bispecific antibody platform for hard-to-treat targets.
Leadership change
AppointmentsSwiss biotech company Anaveon has appointed a new Chief Executive Officer. As the company announced in March, experienced biopharma executive Thaminda Ramanayake will take over the leadership of the Basel-based firm.
Novartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapy
Latest NewsNovartis is pressing ahead with its aggressive expansion strategy in oncology, striking again: the Basel-based group is acquiring a novel PI3Kalpha inhibitor from Synnovation Therapeutics for up to USD 3 billion.